期刊
CANCERS
卷 13, 期 19, 页码 -出版社
MDPI
DOI: 10.3390/cancers13195024
关键词
BET inhibition; diffuse large B-cell lymphoma; RAS GTPase; Rho GTPase; IQGAP3; PI3K; migration
类别
资金
- Featured Areas Research Center Program within Ministry of Education, Taiwan
- Ministry of Science and Technology, Taiwan [MOST 108-2314-B-010-020-MY3, MOST-109-2320-B-010-042, MOST 109-2314-B-182-064-MY3]
- National Health Research Institutes, Taiwan [NHRI-EX109-10919BI]
- Chang-Gung Memorial Hospital [CMRPG6E0283, CORPG6K0011/21]
- Featured Areas Research Center Program within Ministry of Education
- Center of Excellence for Cancer Research from Ministry of Health and Welfare [MOHW110-TDU-B-211-144019]
The BET inhibitor JQ1 abrogates amoeboid movement of DLBCL cells through restrained RAS signaling and MYC-mediated suppression of GTP-RhoA activity, while also increasing IQGAP3 expression, impacting the prognosis of specific DLBCL patients. Inhibitors targeting both BET and RAS activities effectively suppress DLBCL dissemination in vivo, suggesting their potential synergistic therapeutic effect for specific DLBCL subtypes.
Simple Summary: The inhibitors of BET proteins represent a promising class of therapeutic agents that target the oncogenic activity of MYC and repress DLBCL cell migration, but the mechanism of such repression remains elusive. Herein, we found that BET inhibitor JQ1 abrogated the amoeboid movement of DLBCL cells through a small GTPase-driven mechanism, including both restrained RAS signaling and MYC-mediated suppression of GTP-RhoA activity. BET inhibition drastically increased the expression of a GTPase regulatory protein, the IQ motif containing GTPase activating protein 3 (IQGAP3), in DLBCL. Proteomics-based re-stratification identified a specific subgroup of DLBCL patients whose tumors harbored an enhanced PI3K activity and had an inferior survival, whereas a lower IQGAP3 expression level further portended a very dismal outcome for those patients. The inhibitors of both BET and RAS (through attenuated PI3K signaling) activities effectively ameliorated the outspread of in vivo DLBCL tumors, indicating the potential of their synergism in the treatment of specific DLBCL subtypes. Phenotypic heterogeneity and molecular diversity make diffuse large B-cell lymphoma (DLBCL) a challenging disease. We recently illustrated that amoeboid movement plays an indispensable role in DLBCL dissemination and inadvertently identified that the inhibitor of bromodomain and extra-terminal (BET) proteins JQ1 could repress DLBCL migration. To explore further, we dissected the impacts of BET inhibition in DLBCL. We found that JQ1 abrogated amoeboid movement of DLBCL cells through both restraining RAS signaling and suppressing MYC-mediated RhoA activity. We also demonstrated that BET inhibition resulted in the upregulation of a GTPase regulatory protein, the IQ motif containing GTPase activating protein 3 (IQGAP3). IQGAP3 similarly exhibited an inhibitory effect on RAS activity in DLBCL cells. Through barcoded mRNA/protein profiling in clinical samples, we identified a specific subgroup of DLBCL tumors with enhanced phosphatidylinositol-3-kinase (PI3K) activity, which led to an inferior survival in these patients. Strikingly, a lower IQGAP3 expression level further portended those with PI3K-activated DLBCL a very dismal outcome. The inhibition of BET and PI3K signaling activity led to effective suppression of DLBCL dissemination in vivo. Our study provides an important insight into the ongoing efforts of targeting BET proteins as a therapeutic approach for DLBCL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据